LIVIVO - Search results -

Search results

Result 1 - 10 of total 66

Search options

Article ; Online: Durable Major Response With Pazopanib in Recurrent, Heavily Pretreated Metastatic Esthesioneuroblastoma Harboring a Fumarate Hydratase Mutation.

Spengler, Marianne / Wheelden, Megan / Mackley, Heath B / Drabick, Joseph J

JCO precision oncology

2021 Volume 5

MeSH term(s)	Aged ; Esthesioneuroblastoma, Olfactory/drug therapy ; Esthesioneuroblastoma, Olfactory/genetics ; Esthesioneuroblastoma, Olfactory/secondary ; Female ; Fumarate Hydratase/genetics ; Humans ; Indazoles/therapeutic use ; Mutation ; Nasal Cavity ; Neoplasm Recurrence, Local/drug therapy ; Nose Neoplasms/drug therapy ; Nose Neoplasms/genetics ; Nose Neoplasms/pathology ; Pyrimidines/therapeutic use ; Remission Induction ; Retreatment ; Sulfonamides/therapeutic use ; Time Factors
Chemical Substances	Indazoles ; Pyrimidines ; Sulfonamides ; pazopanib (7RN5DR86CK) ; Fumarate Hydratase (EC 4.2.1.2)
Language	English
Publishing date	2021-04-19
Publishing country	United States
Document type	Case Reports ; Journal Article
ISSN	2473-4284
ISSN (online)	2473-4284
DOI	10.1200/PO.20.00486
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Nonsecretory and Light Chain Escape in Patients With Multiple Myeloma.

Patel, Urmeel H / Drabick, Joseph J / Malysz, Jozef / Talamo, Giampaolo

Clinical lymphoma, myeloma & leukemia

2018 Volume 18, Issue 12, Page(s) e515–e519

Abstract: Background: Multiple myeloma (MM) is characterized by the secretion of monoclonal protein by malignant plasma cells in the vast majority of cases. We identified and analyzed patterns of disease relapse and progression associated with disappearance of ... ...

Abstract	Background: Multiple myeloma (MM) is characterized by the secretion of monoclonal protein by malignant plasma cells in the vast majority of cases. We identified and analyzed patterns of disease relapse and progression associated with disappearance of the paraprotein ("nonsecretory [NS] escape"), or conversion from production of intact Ig molecule to its associated light chain ("LC escape"). Patients and methods: We retrospectively reviewed medical records and a database of 791 consecutive patients with symptomatic MM. Results: Twenty-eight (3.5%) patients had disease evolution associated with either NS (n = 13) or LC (n = 15) escape. The event occurred at a median of 37 months (range, 3-156 months) after the diagnosis of MM, and after a median of 3 chemotherapy regimens (range, 1-8 regimens). Presence of extramedullary disease at progression was detected in 8 (29%) patients. Sensitivity to chemotherapy before and after escape was present in 21 (75%) and 14 (50%) patients, respectively. After a median follow-up of 55 months, 19 (68%) patients died, and progressive MM was the cause of death in 18 patients. The median overall survival after escape was 20 months (95% confidence interval, 9-25 months), and no significant difference was found between the NS and LC groups (P = .44). The median overall survival after diagnosis of MM was worse in patients with NS/LC escape than in those without escape (52 vs. 94 months; P = .018). Conclusions: Our study describes the largest series of NS and LC escape in MM to date. The development of this phenomenon is associated with more aggressive clinical features, frequent resistance to chemotherapy, and worse clinical outcome.
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Immunoglobulin A/blood ; Immunoglobulin G/blood ; Immunoglobulin Light Chains/blood ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Multiple Myeloma/blood ; Multiple Myeloma/diagnosis ; Multiple Myeloma/mortality ; Multiple Myeloma/therapy ; Myeloma Proteins ; Plasma Cells/metabolism ; Retrospective Studies
Chemical Substances	Immunoglobulin A ; Immunoglobulin G ; Immunoglobulin Light Chains ; Myeloma Proteins ; multiple myeloma M-proteins
Language	English
Publishing date	2018-07-04
Publishing country	United States
Document type	Journal Article
ZDB-ID	2540992-X
ISSN	2152-2669 ; 2152-2650
ISSN (online)	2152-2669
ISSN	2152-2650
DOI	10.1016/j.clml.2018.06.028
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5903: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Novel approaches in cancer immunotherapy -- a light at the end of the tunnel.

Joshi, Monika / Pal, Sumanta K / Drabick, Joseph J

Discovery medicine

2016 Volume 21, Issue 118, Page(s) 479–487

Abstract: After decades of disappointments, the use of immunotherapy in cancer has finally come of age and resulted in a real paradigm shift in cancer treatment across many tumor types. With the advent of novel immunotherapies based on increasing understanding of ... ...

Abstract	After decades of disappointments, the use of immunotherapy in cancer has finally come of age and resulted in a real paradigm shift in cancer treatment across many tumor types. With the advent of novel immunotherapies based on increasing understanding of the human immune system, cure has become a real possibility for many patients. The development of cancer vaccines, immune checkpoint inhibitors, chimeric antigen receptor T cell, oncolytic virus based immunotherapy to name a few have given hope to patients. One of the most exciting developments in the era of immunotherapy has been the discovery of checkpoint inhibitors causing blockade of two important immune pathways -- cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death receptor-1 (PD-1), resulting in empowerment of anti-tumor immunity. However, only a select group of patients respond to these immunotherapies, highlighting a need for novel strategies that could help transform the non-responders to responders' category. This article highlights various immunotherapeutic agents and strategies using them and other modalities in the treatment of solid tumors.
MeSH term(s)	Antibodies, Monoclonal/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Autoimmunity ; CTLA-4 Antigen/antagonists & inhibitors ; Cancer Vaccines/therapeutic use ; Combined Modality Therapy ; Humans ; Immunity, Cellular ; Immunologic Factors/therapeutic use ; Immunotherapy/methods ; Immunotherapy/trends ; Neoplasms/immunology ; Neoplasms/therapy ; Oncolytic Viruses/immunology ; Programmed Cell Death 1 Receptor/antagonists & inhibitors
Chemical Substances	Antibodies, Monoclonal ; CTLA-4 Antigen ; CTLA4 protein, human ; Cancer Vaccines ; Immunologic Factors ; PDCD1 protein, human ; Programmed Cell Death 1 Receptor
Language	English
Publishing date	2016-06
Publishing country	United States
Document type	Journal Article
ISSN	1944-7930
ISSN (online)	1944-7930
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Need for a personalized approach for muscle invasive bladder cancer: role of tumor biology in response to neoadjuvant chemotherapy.

Joshi, Monika / Warrick, Joshua I / Yin, Ming / Holder, Sheldon L / Drabick, Joseph J

Translational andrology and urology

2019 Volume 8, Issue Suppl 1, Page(s) S99–S103

Language	English
Publishing date	2019-04-29
Publishing country	China
Document type	Editorial ; Comment
ZDB-ID	2851630-8
ISSN	2223-4691 ; 2223-4691 ; 2223-4683
ISSN (online)	2223-4691
ISSN	2223-4691 ; 2223-4683
DOI	10.21037/tau.2018.12.04
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Prognosis and treatment of non-metastatic primary and secondary breast angiosarcoma: a comparative study.

Yin, Ming / Wang, Wenge / Drabick, Joseph J / Harold, Harvey A

BMC cancer

2017 Volume 17, Issue 1, Page(s) 295

Abstract: Background: Breast angiosarcoma is a rare malignancy with limited publications confined to small retrospective case reviews and case reports. Knowledge of this disease is limited because information from previous studies is insufficient and inconsistent. ...

Abstract	Background: Breast angiosarcoma is a rare malignancy with limited publications confined to small retrospective case reviews and case reports. Knowledge of this disease is limited because information from previous studies is insufficient and inconsistent. Methods: We obtained data from the Surveillance, Epidemiology, and End Results Program for non-metastatic primary and secondary breast angiosarcoma, and performed analysis to determine clinicopathological characteristics and estimate their associations with overall survival (OS). Results: Median age was 50-54 years in primary breast angiosarcoma and 70-74 years in secondary breast angiosarcoma, while median OS was 93 and 32 months, respectively. Age, tumor grade and tumor spread were associated with poor survival outcomes. Compared with primary breast angiosarcoma, patients with secondary breast angiosarcoma had a "nominal" increased death risk (HR = 1.89, 95% CI, 1.43-2.50, p < 0.001), which was driven by older age and more aggressive tumor phenotype at presentation. Mastectomy was associated with worse OS compared with breast conservative surgery (BCS) (adjHR = 2.47, 95% CI, 1.29-4.74) in primary angiosarcoma patients. Adjuvant radiation was associated with worse OS in secondary angiosarcoma patients (adjHR =1.77, 95% CI, 1.01-3.12). Conclusions: There is a "nominal" increased death risk in secondary breast angiosarcoma due to advanced clinicopathological features. Both BCS and mastectomy are feasible in primary and secondary angiosarcoma if R0 can be achieved. Routine radiation in unselected breast angiosarcoma should be cautious because there is no survival benefit in primary AS and appeared to be associated with a worse OS in secondary AS.
MeSH term(s)	Aged ; Breast Neoplasms/pathology ; Breast Neoplasms/therapy ; Combined Modality Therapy ; Female ; Follow-Up Studies ; Hemangiosarcoma/pathology ; Hemangiosarcoma/therapy ; Humans ; Middle Aged ; Neoplasm Grading ; Neoplasms, Second Primary/pathology ; Neoplasms, Second Primary/therapy ; Prognosis ; Retrospective Studies ; Survival Rate
Language	English
Publishing date	2017--27
Publishing country	England
Document type	Comparative Study ; Journal Article
ISSN	1471-2407
ISSN (online)	1471-2407
DOI	10.1186/s12885-017-3292-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis.

Sha, Congzhou M / Lehrer, Eric J / Hwang, Clara / Trifiletti, Daniel M / Mackley, Heath B / Drabick, Joseph J / Zaorsky, Nicholas G

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

2020 Volume 151, Page(s) 141–148

Abstract: Background and purpose: Immune checkpoint inhibitor with radiation therapy (ICI + RT) is under investigation for improved patient outcome, so we performed a systematic review/meta-analysis of toxicities for ICI + RT compared to immune checkpoint ... ...

Abstract	Background and purpose: Immune checkpoint inhibitor with radiation therapy (ICI + RT) is under investigation for improved patient outcome, so we performed a systematic review/meta-analysis of toxicities for ICI + RT compared to immune checkpoint inhibitor (ICI) therapy alone. Materials and methods: A PRISMA-compliant systematic review of studies in MEDLINE (PubMed) and in the National Comprehensive Cancer Network guidelines was conducted, with primary outcome grade 3 + toxicity. Criteria for ICI alone were: phase III/IV trials that compared immunotherapy to placebo, chemotherapy, or alternative immunotherapy; and for ICI + RT: prospective/retrospective studies with an arm treated with ICI + RT. Meta-analysis was performed by random effects models using the DerSimonian and Laird method. The I Results: This meta-analysis included 51 studies (n = 15,398), with 35 ICI alone (n = 13,956) and 16 ICI + RT studies (n = 1,442). Our models showed comparable grade 3-4 toxicities in ICI + RT (16.3%; 95% CI, 11.1-22.3%) and ICI alone (22.3%; 95% CI, 18.1-26.9%). Stratification by timing of radiation and irradiated site showed no significant differences, but anti-CTLA-4 therapy and melanoma showed increased toxicity. The grade 5 toxicities were 1.1% and 1.9% for ICI alone and ICI + RT respectively. There was significant heterogeneity, but not publication bias. Conclusions: The random effects model showed comparable grade 3-4 toxicity in using ICI + RT compared to ICI alone in CNS melanoma metastases, NSCLC, and prostate cancer. ICI + RT is safe for future clinical trials in these cancers.
MeSH term(s)	Carcinoma, Non-Small-Cell Lung ; Humans ; Immune Checkpoint Inhibitors ; Lung Neoplasms ; Male ; Prospective Studies ; Retrospective Studies
Chemical Substances	Immune Checkpoint Inhibitors
Language	English
Publishing date	2020-07-24
Publishing country	Ireland
Document type	Journal Article ; Meta-Analysis ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review ; Systematic Review
ZDB-ID	605646-5
ISSN	1879-0887 ; 0167-8140
ISSN (online)	1879-0887
ISSN	0167-8140
DOI	10.1016/j.radonc.2020.07.035
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1926: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Primary female breast sarcoma: clinicopathological features, treatment and prognosis.

Yin, Ming / Mackley, Heath B / Drabick, Joseph J / Harvey, Harold A

Scientific reports

2016 Volume 6, Page(s) 31497

Abstract: Primary breast sarcoma (PBS) is a rare and heterogeneous group of malignancies with limited publications. We obtained data from the Surveillance, Epidemiology, and End Results Program and performed analysis to determine clinicopathological ... ...

Abstract	Primary breast sarcoma (PBS) is a rare and heterogeneous group of malignancies with limited publications. We obtained data from the Surveillance, Epidemiology, and End Results Program and performed analysis to determine clinicopathological characteristics of PBS and estimate their associations with overall survival (OS) and cancer-specific survival (CSS). Median age of PBS was 55-59 years and median OS was 108 months. Age, overlap or entire breast involvement, tumor histology, and tumor spread were associated with poor survival outcomes. In the multivariable analysis, tumor size, lymph node involvement, distant metastasis and histologic grade were correlated with survival outcomes (P < 0.001). In M0 patients, mastectomy was associated with worse survival outcomes compared with breast conservative surgery (BCS) (adjusted hazard ratio [adjHR], 1.80; 95% CI, 1.31-2.47), regardless of tumor size, tumor grade, tumor histology or radiation history. Adjuvant radiation improved survival outcomes in patients with tumor size >5 cm (adjHR, 0.63; 95% CI, 0.43-0.91), but not in patients with tumor size ≤ 5 cm. Our study demonstrated clinicopathological characteristics of PBS in the US population and supports performing BCS if R0 resection can be achieved, with radiation if tumor size is over 5 cm.
Language	English
Publishing date	2016-08-11
Publishing country	England
Document type	Journal Article
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/srep31497
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Full text

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: Poking CD40 for cancer therapy, another example of the Goldilocks effect.

Drabick, Joseph J / Schell, Todd D

Cancer biology & therapy

2010 Volume 10, Issue 10, Page(s) 994–996

MeSH term(s)	Antibodies, Monoclonal/pharmacokinetics ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents/pharmacokinetics ; Antineoplastic Agents/therapeutic use ; CD40 Antigens/agonists ; Humans ; Neoplasms/drug therapy ; Neoplasms/immunology ; Remission Induction
Chemical Substances	Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents ; CD40 Antigens ; selicrelumab (0O39RGI33V)
Language	English
Publishing date	2010-11-15
Publishing country	United States
Document type	Journal Article ; Comment
ZDB-ID	2146305-0
ISSN	1555-8576 ; 1538-4047
ISSN (online)	1555-8576
ISSN	1538-4047
DOI	10.4161/cbt.10.10.13976
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5887: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Group-led creative writing and behavioural health in cancer: a randomised clinical trial.

Nesterova, Darya / Zhu, Junjia / Kramer, Courtney / Vasekar, Monali / Truica, Cristina / Joshi, Aditya / Hayes, Michael / Kessler, Jolene / Saunders, Erika F H / Drabick, Joseph J / Joshi, Monika

BMJ supportive & palliative care

2021 Volume 12, Issue 1, Page(s) 91–98

Abstract: Background: Cancer diagnosis can adversely affect mental well-being and overall clinical outcome. We evaluated the efficacy of a group-led creative writing workshop (CWW) on mood in patients with cancer prospectively.: Methods: We conducted a single- ... ...

Abstract	Background: Cancer diagnosis can adversely affect mental well-being and overall clinical outcome. We evaluated the efficacy of a group-led creative writing workshop (CWW) on mood in patients with cancer prospectively. Methods: We conducted a single-institution phase II study. Sixty adult patients with cancer (any type or stage) were randomised 2:1 to CWW (4×CWW sessions, bimonthly over 8 weeks) versus active control (AC) (independent writing at home with the help of a book, four sessions, bimonthly over 8 weeks). The total study duration was 6 months with a follow-up of up to 3 months. Primary objective: changes in overall mood, depression and anxiety symptoms before and after intervention in both arms. Emotional Thermometer Scale (ETS) was used to assess changes in patients' mood. Additionally, the Patient Health Questionnaire (PHQ)-9 and General Anxiety Disorder Scale (GAD)-7 were used to evaluate depression and anxiety symptoms. Results: Of 50 evaluable patients (CWW 34, AC 17), 26 patients in the CWW arm attended at least one class and 19 attended at least four classes. Patients in CWW had significant immediate improvement in the overall ETS (post vs preclass scores; p<0.0001, 95% CI -4.31 to -2.47). Four of the five subscale ETS scores were significantly lower for the CWW arm: distress (p=0.0346, 95% CI -2.6 to -0.1), anxiety (p=0.0366, 95% CI -4.1 to -0.2), depression (p=0.0441, 95% CI -3.9 to -0.1) and anger (p=0.0494, 95% CI -3.3 to 0). No significant differences were seen in the AC arm. No significant differences were observed in the PHQ-9 or the GAD-7 scores. Conclusion: CWW had a positive effect on mood based on ETS scores, suggesting a potential therapeutic benefit among patients with cancer.
MeSH term(s)	Adult ; Affect ; Anxiety/therapy ; Cognitive Behavioral Therapy ; Depression/therapy ; Humans ; Neoplasms/complications ; Neoplasms/therapy ; Treatment Outcome ; Writing
Language	English
Publishing date	2021-01-09
Publishing country	England
Document type	Clinical Trial, Phase II ; Journal Article ; Randomized Controlled Trial
ISSN	2045-4368
ISSN (online)	2045-4368
DOI	10.1136/bmjspcare-2020-002463
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Medical Service Use and Charges for Cancer Care in 2018 for Privately Insured Patients Younger Than 65 Years in the US.

Zaorsky, Nicholas G / Khunsriraksakul, Chachrit / Acri, Samantha L / Liu, Dajiang J / Ba, Djibril M / Lin, John L / Liu, Guodong / Segel, Joel E / Drabick, Joseph J / Mackley, Heath B / Leslie, Douglas L

JAMA network open

2021 Volume 4, Issue 10, Page(s) e2127784

Abstract: Importance: Currently, there are limited published data regarding resource use and spending on cancer care in the US.: Objective: To characterize the most frequent medical services provided and the associated spending for privately insured patients ... ...

Abstract	Importance: Currently, there are limited published data regarding resource use and spending on cancer care in the US. Objective: To characterize the most frequent medical services provided and the associated spending for privately insured patients with cancer in the US. Design, setting, and participants: This cohort study used data from the MarketScan database for the calendar year 2018 from a sample of 27.1 million privately insured individuals, including patients with a diagnosis of the 15 most prevalent cancers, predominantly from large insurers and self-insured employers. Overall societal health care spending was estimated for each cancer type by multiplying the mean total spending per patient (estimated from MarketScan) by the number of privately insured patients living with that cancer in 2018, as reported by the National Cancer Institute's Surveillance, Epidemiology, and End Results program. Analyses were performed from February 1, 2018, to July 8, 2021. Exposures: Evaluation and management as prescribed by treating care team. Main outcomes and measures: Current Procedural Terminology and Healthcare Common Procedure Coding System codes based on cancer diagnosis code. Results: The estimated cost of cancer care in 2018 for 402 115 patients with the 15 most prevalent cancer types was approximately $156.2 billion for privately insured adults younger than 65 years in the US. There were a total of 38.4 million documented procedure codes for 15 cancers in the MarketScan database, totaling $10.8 billion. Patients with breast cancer contributed the greatest total number of services (10.9 million [28.4%]), followed by those with colorectal cancer (3.9 million [10.2%]) and prostate cancer (3.6 million [9.4%]). Pathology and laboratory tests contributed the highest number of services performed (11.7 million [30.5%]), followed by medical services (6.3 million [16.4%]) and medical supplies and nonphysician services (6.1 million [15.9%]). The costliest cancers were those of the breast ($3.4 billion [31.5%]), followed by lung ($1.1 billion [10.2%]) and colorectum ($1.1 billion [10.2%]). Medical supplies and nonphysician services contributed the highest total spent ($4.0 billion [37.0%]), followed by radiology ($2.1 billion [19.4%]) and surgery ($1.8 billion [16.7%]). Conclusions and relevance: This analysis suggests that patients with breast, colorectal, and prostate cancers had the greatest number of services performed, particularly for pathology and laboratory tests, whereas patients with breast, lung, lymphoma, and colorectal cancer incurred the greatest costs, particularly for medical supplies and nonphysician services. The cost of cancer care in 2018 for the 15 most prevalent cancer types was estimated to be approximately $156.2 billion for privately insured adults younger than 65 years in the US.
MeSH term(s)	Adult ; Cohort Studies ; Female ; For-Profit Insurance Plans/standards ; For-Profit Insurance Plans/statistics & numerical data ; Health Care Costs/statistics & numerical data ; Humans ; Male ; Middle Aged ; Neoplasms/economics ; Neoplasms/epidemiology ; Patient Acceptance of Health Care/statistics & numerical data ; United States/epidemiology
Language	English
Publishing date	2021-10-01
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ISSN	2574-3805
ISSN (online)	2574-3805
DOI	10.1001/jamanetworkopen.2021.27784
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED